Greenberg Lab Research
We're excited to share the following news updates:
- Roger Greenberg has been selected as the recipient of the 2023 William L. Gerald Award, which is given annually by the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center. Dr. Gerald was a former member of their faculty who was a pioneer in the molecular characterization of cancer. The award is conferred annually to “a pathologist who has made outstanding contributions to research in cancer pathology, who has helped in elucidating knowledge gaps in their field of specialization, and whose career trajectory suggests that their biggest breakthroughs are still to come.”
- Tianpeng Zhang was selected for a talk at the Gordon Research Conference in February 2023
- Tianpeng Zhang received an AFCRI postdoctoral Fellowship Award
Germline mutations to the Breast Cancer 1 (BRCA1) or Breast Cancer 2 (BRCA2) genes are the major cause of hereditary breast and ovarian cancer susceptibility. Clinical BRCA1 and BRCA2 mutations render cells deficient in error-free mechanisms of DNA repair known as homologous recombination, implicating these activities in tumor suppression and response to genotoxic therapies.
Our work has revealed a molecular understanding for how BRCA1 recognizes DNA damage and competes with opposing DNA repair proteins to control genome integrity. We have demonstrated that an interaction between the BRCA1 BRCT domain and the RAP80 ubiquitin binding protein targets BRCA1 to K63-linked ubiquitin structures present at DNA damage sites. RAP80 ubiquitin interaction motifs (UIMs) provide a ubiquitin recognition element to target BRCA1 and a K63-ubiquitin specific deubiquitinating enzyme BRCC36 to DNA double strand breaks. Each of these activities is required for appropriate DNA damage checkpoint and repair responses (Sobhian et al. Science 2007; Shao et al. Genes&Dev 2009; Tang et al. Nat Struct & Mol Biol 2013; Jiang et al. Genes Dev 2015; Zeqiraj et al. Mol Cell 2015). Cancer causing BRCA1 BRCT mutants fail to interact with RAP80 and consequently demonstrate inefficient recruitment to DNA damage sites. Moreover, germline mutations in RAP80 and Abraxas are present in familial breast cancer (Nikkila et al. Oncogene 2009; Solyom et al Sci Transl Med 2012) and biallelic BRCA1 mutations cause a new subtype of Fanconi Anemia known as Fanc-S (Domchek et al. Cancer Discov 2013; Sawyer et al Cancer Discov 2015). Thus, a series of ordered events involving ubiquitin recognition, breakdown and synthesis are required for BRCA1-dependent DNA damage responses and tumor suppression.
A second area of interest is the complex relationship between chromatin structure and DNA repair. We have developed several novel systems to investigate interrelationships between chromatin structure and DNA double strand break (DSB) repair. This was instrumental to our discoveries that DSBs silence transcription for multiple kilobases of chromatin in cis to the site of DNA damage (Shanbhag et al. Cell 2010), and that chromatin environment affects DNA repair mechanism choice and sensitivity to PARP inhibitors (Tang et al. Nat Struct Mol Biol 2013). More recently, we have developed methodologies to directly monitor homologous recombination at telomeres, a first for any genomic location in mammalian cells. This enabled our discovery of a novel form of homology directed repair that is responsible for alternative telomere length maintenance mechanisms in approximately 15% of human cancers (Cho et al. Cell 2014; Dilley et al. Nature 2016; Verma et al. Genes Dev 2019).
In addition to these studies involving acute DNA damage responses, we have recently determined the basis for the longstanding observation that DNA damage activates innate and adaptive immune responses (Harding et al. Nature 2017; Walden, Tian et al. Nature 2019). Our findings reveal that mitotic progression in the presence of DNA damage results in micronuclei within the cytoplasm that are recognized by the pattern recognition receptor cGAS. This produces inflammatory cytokine signals that activate anti-tumor immune responses to eradicate cells within the primary tumor and distal metastases. We will continue to use these systems to determine how DNA damage response mechanisms contributes to genome integrity, cancer etiology and response to therapy.
Perelman School of Medicine Events
PCGI Trainee Seminar
Monday, April 25, 2022
Timothy Lippert (Greenberg Lab) presenting “DNA damage-driven inflammasome activation in BRCA-deficient ovarian cancer”
Jon Acosta (Feldser Lab) presenting “Elucidating the molecular determinants of p53-mediated pleiotropic effects in SCLC”